Dr Reddy's recalls Rivastigmine Tartrate capsules from US
Hyderabad, Aug 20 : Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'.A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA).According to a notification issued by the agency, the batch was manufactured at...
A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA).
According to a notification issued by the agency, the batch was manufactured at DRL's Ltd, Bachupally unit and the recall was initiated under "Class II" classification.
Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease.
According to the US health regulator, Class II recall is a situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at email@example.com. Contact no. 011-43720751